Vicky Makker, MD, Antonio Gonzalez-Martin, MD,
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
October 28, 2025 at 1:38 PM
Vicky Makker, MD, Antonio Gonzalez-Martin, MD,
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
October 17, 2025 at 7:08 PM
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
🎥 Angeles Secord, MD, of @dukecancer.bsky.social shares final Phase II PICCOLO results: mirvetuximab soravtansine shows durable responses & good survival in FRα+ platinum-sensitive ovarian cancer:
➡️https://buff.ly/ysRSWzX⬅️
@ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM
➡️https://buff.ly/ysRSWzX⬅️
@ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM
PICCOLO: final analysis of mirvetuximab soravtansine in ovarian cancer - VJOncology
Angeles Secord, MD, Duke Cancer Institute, Durham, NC, discusses the final analysis of the Phase II PICCOLO study (NCT05041257), which...
buff.ly
September 4, 2025 at 5:18 PM
🎥 Angeles Secord, MD, of @dukecancer.bsky.social shares final Phase II PICCOLO results: mirvetuximab soravtansine shows durable responses & good survival in FRα+ platinum-sensitive ovarian cancer:
➡️https://buff.ly/ysRSWzX⬅️
@ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM
➡️https://buff.ly/ysRSWzX⬅️
@ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM
Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer #gynsm #oncology www.onclive.com/view/sintili...
Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer
Extended follow-up showed sintilimab plus anlotinib yielded durable efficacy and tolerability in PD-L1–positive recurrent/metastatic cervical cancer.
www.onclive.com
August 11, 2025 at 7:51 PM
Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer #gynsm #oncology www.onclive.com/view/sintili...
Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer @ascocancer.bsky.social #ASCO25 #gynsm #oncology www.onclive.com/view/explora...
Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer
An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.
www.onclive.com
June 3, 2025 at 9:51 PM
Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer @ascocancer.bsky.social #ASCO25 #gynsm #oncology www.onclive.com/view/explora...
Just spoke with Alexander Olawaiye, MD, of UPMC Hillman Cancer Center, about the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. Keep an eye out for more key takeaways from this study! @ascocancer.bsky.social #ASCO25 #gynsm
May 31, 2025 at 7:47 PM
Just spoke with Alexander Olawaiye, MD, of UPMC Hillman Cancer Center, about the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. Keep an eye out for more key takeaways from this study! @ascocancer.bsky.social #ASCO25 #gynsm
There are multiple points along the #cancertreatment pathway where a #secondopinion is an important option. Click below to register for the @PinkRibbonGood webinar, Beyond Diagnosis: The Power of a 2nd Opinion this Thursday, May 8, 12-1pmET:
bit.ly/4iMHaHS
#BCSM #GYNSM #MEDSKY
bit.ly/4iMHaHS
#BCSM #GYNSM #MEDSKY
Join us monthly as PRG brings trusted experts to your screen, and hope every step of the way. 🩵💗
YouTube video by Pink Ribbon Good
www.youtube.com
May 5, 2025 at 9:06 PM
There are multiple points along the #cancertreatment pathway where a #secondopinion is an important option. Click below to register for the @PinkRibbonGood webinar, Beyond Diagnosis: The Power of a 2nd Opinion this Thursday, May 8, 12-1pmET:
bit.ly/4iMHaHS
#BCSM #GYNSM #MEDSKY
bit.ly/4iMHaHS
#BCSM #GYNSM #MEDSKY
PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer #SGO25 #ovca #gynsm www.onclive.com/view/parp-in...
PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer
Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
www.onclive.com
April 15, 2025 at 6:28 PM
PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer #SGO25 #ovca #gynsm www.onclive.com/view/parp-in...
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer #SGO2025 #gynsm #oncology www.onclive.com/view/dual-pd...
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer
Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.
www.onclive.com
April 8, 2025 at 1:08 PM
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer #SGO2025 #gynsm #oncology www.onclive.com/view/dual-pd...
Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer #gynsm #oncology www.onclive.com/view/tisotum...
March 27, 2025 at 4:27 PM
Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer #gynsm #oncology www.onclive.com/view/tisotum...
"Matt Hellmann [VP Early Oncology Dev] told @endpts.com
in interview that there have been very few advances in 2nd-line endometrial cancer over the past several decades. For context, chemotherapy currently produces a response rate in the 20% range & a PFS of 4 to 5 months, he said" #gynsm #SGO2025
in interview that there have been very few advances in 2nd-line endometrial cancer over the past several decades. For context, chemotherapy currently produces a response rate in the 20% range & a PFS of 4 to 5 months, he said" #gynsm #SGO2025
Encouraging clinical trial data from AstraZeneca & ADC in metastatic endometrial cancer: 2 mg/kg dose of puxitatug samrotecan/P-sam achieved a 34.6% objective response rate in patients w/ B7-H4 positive advanced or metastatic endometrial cancer in Phase 1/2a trial. endpts.com/astrazeneca-... 1/n
March 17, 2025 at 2:04 PM
"Matt Hellmann [VP Early Oncology Dev] told @endpts.com
in interview that there have been very few advances in 2nd-line endometrial cancer over the past several decades. For context, chemotherapy currently produces a response rate in the 20% range & a PFS of 4 to 5 months, he said" #gynsm #SGO2025
in interview that there have been very few advances in 2nd-line endometrial cancer over the past several decades. For context, chemotherapy currently produces a response rate in the 20% range & a PFS of 4 to 5 months, he said" #gynsm #SGO2025
The 2.4 mg/kg dose hit a 38.5% ORR, according to data presented Saturday at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Seattle. #SGO2025 #gynsm endpts.com/astrazeneca-...
AstraZeneca reveals first-in-human data for B7-H4-targeting ADC in endometrial cancer
AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response and survival results in endometrial cancer patients enrolled in an early s...
endpts.com
March 17, 2025 at 2:02 PM
The 2.4 mg/kg dose hit a 38.5% ORR, according to data presented Saturday at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Seattle. #SGO2025 #gynsm endpts.com/astrazeneca-...
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer #SGOMtg #SGO25 #gynsm #oncology www.onclive.com/view/puxitat...
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer
Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.
www.onclive.com
March 16, 2025 at 7:33 PM
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer #SGOMtg #SGO25 #gynsm #oncology www.onclive.com/view/puxitat...
Good morning Seattle! 🌆
☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!
#SGOMtg #AM25IMPACT #gynsm
☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!
#SGOMtg #AM25IMPACT #gynsm
March 15, 2025 at 1:30 PM
Good morning Seattle! 🌆
☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!
#SGOMtg #AM25IMPACT #gynsm
☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!
#SGOMtg #AM25IMPACT #gynsm
Tonight at 7:30pm #YaleCancerAnswers host Dr. Eric Winer talks with #gynoncologist Dr. Elena Ratner about the use of #roboticsurgery to treat #gynecolociccancers.
🎧 Listen live- WNPR
🔁 Download- Apple Podcasts
💻 Watch- YouTube
#gynsm
@yaleschoolofmed.bsky.social
🎧 Listen live- WNPR
🔁 Download- Apple Podcasts
💻 Watch- YouTube
#gynsm
@yaleschoolofmed.bsky.social
March 2, 2025 at 8:07 PM
Tonight at 7:30pm #YaleCancerAnswers host Dr. Eric Winer talks with #gynoncologist Dr. Elena Ratner about the use of #roboticsurgery to treat #gynecolociccancers.
🎧 Listen live- WNPR
🔁 Download- Apple Podcasts
💻 Watch- YouTube
#gynsm
@yaleschoolofmed.bsky.social
🎧 Listen live- WNPR
🔁 Download- Apple Podcasts
💻 Watch- YouTube
#gynsm
@yaleschoolofmed.bsky.social
The @fda.gov Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer #gynsm #oncology www.onclive.com/view/fda-gra...
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer
The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.
www.onclive.com
February 5, 2025 at 5:19 PM
The @fda.gov Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer #gynsm #oncology www.onclive.com/view/fda-gra...
Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer #SGOmtg #ovca #gynsm www.onclive.com/view/trend-t...
Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer
Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.
www.onclive.com
January 31, 2025 at 9:42 PM
Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer #SGOmtg #ovca #gynsm www.onclive.com/view/trend-t...
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
#SGOmtg #gynsm #oncology
www.onclive.com/view/molecul...
#SGOmtg #gynsm #oncology
www.onclive.com/view/molecul...
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.
www.onclive.com
January 30, 2025 at 10:52 PM
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
#SGOmtg #gynsm #oncology
www.onclive.com/view/molecul...
#SGOmtg #gynsm #oncology
www.onclive.com/view/molecul...
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer #SGOmtg #gynsm #oncology www.onclive.com/view/observa...
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer
An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.
www.onclive.com
January 30, 2025 at 10:30 PM
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer #SGOmtg #gynsm #oncology www.onclive.com/view/observa...
ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer #ovca #gynsm #oncology www.onclive.com/view/adc-ane...
ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer
Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.
www.onclive.com
January 30, 2025 at 3:14 PM
ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer #ovca #gynsm #oncology www.onclive.com/view/adc-ane...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer #gynsm #oncology www.onclive.com/view/europea...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.
www.onclive.com
January 20, 2025 at 5:09 PM
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer #gynsm #oncology www.onclive.com/view/europea...
Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of Mirvetuximab Soravtansine in Ovarian Cancer
#gynsm #oncology #MedEd #MedTwitter
www.onclive.com/view/ocular-...
#gynsm #oncology #MedEd #MedTwitter
www.onclive.com/view/ocular-...
Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of Mirvetuximab Soravtansine in Ovarian Cancer
Ritu Salani, MD, discusses the role of mirvetuximab soravtansine in ovarian cancer and the need for specialist involvement in ocular toxicity management.
www.onclive.com
December 18, 2024 at 8:06 PM
Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of Mirvetuximab Soravtansine in Ovarian Cancer
#gynsm #oncology #MedEd #MedTwitter
www.onclive.com/view/ocular-...
#gynsm #oncology #MedEd #MedTwitter
www.onclive.com/view/ocular-...
USPSTF issues draft guidance for cervical cancer screening that include a self collection option. #gynsm #oncsky www.uspreventiveservicestaskforce.org/uspstf/docum...
Draft Evidence Review: Cervical Cancer: Screening | United States Preventive Services TaskforceShare to FacebookShare to XShare to WhatsAppShare to EmailPrint
www.uspreventiveservicestaskforce.org
December 11, 2024 at 1:25 PM
USPSTF issues draft guidance for cervical cancer screening that include a self collection option. #gynsm #oncsky www.uspreventiveservicestaskforce.org/uspstf/docum...
here you go @kkbadger1 and anyone else with #cancer or a #chronicillness who might want a G-rated #VaccinatedButVulnerable shirt - more styles and colors added. Proceeds to @metavivor. #bcsm #lcsm #crcsm #btsm #gynsm
https://www.bonfire.com/vaccinated-but-vulnerable/
https://www.bonfire.com/vaccinated-but-vulnerable/
Covid doesn't care about cancer | Bonfire
but METAvivor does! We raised $4.4 MILLION for metastatic...
www.bonfire.com
November 17, 2024 at 8:50 PM
here you go @kkbadger1 and anyone else with #cancer or a #chronicillness who might want a G-rated #VaccinatedButVulnerable shirt - more styles and colors added. Proceeds to @metavivor. #bcsm #lcsm #crcsm #btsm #gynsm
https://www.bonfire.com/vaccinated-but-vulnerable/
https://www.bonfire.com/vaccinated-but-vulnerable/